1. Artivion to participate in Oppenheimer MedTech Conference on March 18, 2025. 2. Webcast will be available on Artivion's website for 90 days. 3. Company specializes in aortic disease solutions and operates in over 100 countries.
Participation in a prestigious conference suggests confidence and visibility, potentially boosting investor interest.
The announcement raises awareness of Artivion's offerings, which can drive investor interest and subsequent price action.
The event is imminent, likely to affect stock performance soon after.
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 35th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m. ET on March 18, 2025.
A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.
Artivion
Gilmartin Group LLC
Lance A. Berry
Brian Johnston / Laine Morgan
Executive Vice President & Chief Financial Officer
Phone: 332-895-3222
[email protected]
Phone: 770-419-3355
SOURCE Artivion